Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-09-15

FDA Approved: DESCOVY — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for DESCOVY (emtricitabine and tenofovir alafenamide) submitted by Gilead Sciences, Inc., likely to update labeling …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Descovy (emtricitabine/tenofovir alafenamide)

Snippet

SUPPL AP for DESCOVY (EMTRICITABINE AND TENOFOVIR ALAFENAMIDE)